Pulmonary Hypertension Survival Effects and Treatment Options in Cystic Fibrosis

Overview

Journal Curr Opin Pulm Med

Specialty Pulmonary Medicine

Date 2013 Sep 20

PMID 24048083

Citations 9

Authors

Adriano R Tonelli

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review discusses the current impact of pulmonary hypertension on the outcome and treatment of cystic fibrosis (CF).

Recent Findings: Pulmonary hypertension is commonly encountered in advanced lung diseases such as CF. The prevalence of pulmonary hypertension in CF patients varies based on disease severity and methodology used for diagnosis. Chronic alveolar hypoxia is the most likely cause. The majority of recent studies have shown worse survival in CF patients who develop pulmonary hypertension. The impact of pulmonary hypertension-specific therapies on symptomatology and outcomes in CF patients has not been well studied.

Summary: Pulmonary hypertension is common in patients with CF and it occurs largely because of hypoxemia. The presence of pulmonary hypertension in patients with CF is likely associated with worse outcome; however, it remains unknown whether treatment with pulmonary hypertension-specific therapies would be beneficial.

Citing Articles

Current Blood Eosinophilia Does Not Predict the Presence of Pulmonary Hypertension in Patients with End-Stage Lung Disease.

Barnikel M, Kneidinger N, Gerckens M, Mummler C, Lenoir A, Mertsch P J Clin Med. 2025; 14(4).

PMID: 40004650 PMC: 11856528. DOI: 10.3390/jcm14041120.

Pulmonary Vascular Dysfunctions in Cystic Fibrosis.

Amoakon J, Mylavarapu G, Amin R, Naren A Physiology (Bethesda). 2024; 39(4).

PMID: 38501963 PMC: 11368519. DOI: 10.1152/physiol.00024.2023.

Future Comorbidities in an Aging Cystic Fibrosis Population.

Ticona J, Lapinel N, Wang J Life (Basel). 2023; 13(6).

PMID: 37374088 PMC: 10301499. DOI: 10.3390/life13061305.

Effects of a Long-Term Wearable Activity Tracker-Based Exercise Intervention on Cardiac Morphology and Function of Patients with Cystic Fibrosis.

Anifanti M, Giannakoulakos S, Hatziagorou E, Kampouras A, Tsanakas J, Deligiannis A Sensors (Basel). 2022; 22(13).

PMID: 35808375 PMC: 9269327. DOI: 10.3390/s22134884.

Identification of novel metabolic signatures potentially involved in the pathogenesis of COPD associated pulmonary hypertension.

Choudhury P, Bhattacharya A, Dasgupta S, Ghosh N, Senpupta S, Joshi M Metabolomics. 2021; 17(10):94.

PMID: 34599402 DOI: 10.1007/s11306-021-01845-9.

References

Burghuber O, Salzer-Muhar U, Bergmann H, Gotz M . Right ventricular performance and pulmonary haemodynamics in adolescent and adult patients with cystic fibrosis. Eur J Pediatr. 1988; 148(3):187-92. DOI: 10.1007/BF00441398. View

Venuta F, Tonelli A, Anile M, Diso D, De Giacomo T, Ruberto F . Pulmonary hypertension is associated with higher mortality in cystic fibrosis patients awaiting lung transplantation. J Cardiovasc Surg (Torino). 2012; 53(6):817-20. View

Moskowitz W, Gewitz M, Heyman S, Ruddy R, Scanlin T . Cardiac involvement in cystic fibrosis: early noninvasive detection and vasodilator therapy. Pediatr Pharmacol (New York). 1985; 5(2):139-48. View

Valerio G, Bracciale P, Grazia DAgostino A . Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009; 3(1):15-21. DOI: 10.1177/1753465808103499. View

Lederer D, Bartels M, Schluger N, Brogan F, Jellen P, Thomashow B . Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD. 2012; 9(3):268-75. PMC: 4904720. DOI: 10.3109/15412555.2011.651180. View

Bano-Rodrigo A, Salcedo-Posadas A, Villa-Asensi J, Tamariz-Martel A, Lopez-Neyra A, Blanco-Iglesias E . Right ventricular dysfunction in adolescents with mild cystic fibrosis. J Cyst Fibros. 2012; 11(4):274-80. DOI: 10.1016/j.jcf.2012.03.002. View

Badesch D, Champion H, Gomez Sanchez M, Hoeper M, Loyd J, Manes A . Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S55-S66. DOI: 10.1016/j.jacc.2009.04.011. View

Tissieres P, Nicod L, Barazzone-Argiroffo C, Rimensberger P, Beghetti M . Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension. Ann Thorac Surg. 2004; 78(3):e48-50. DOI: 10.1016/j.athoracsur.2003.12.096. View

Johnson S, Mehta S, Granton J . Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J. 2006; 28(5):999-1004. DOI: 10.1183/09031936.06.00015206. View

10.

Fisher M, Forfia P, Chamera E, Housten-Harris T, Champion H, Girgis R . Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179(7):615-21. PMC: 2720125. DOI: 10.1164/rccm.200811-1691OC. View

11.

Fraser K, Tullis D, Sasson Z, Hyland R, Thornley K, Hanly P . Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest. 1999; 115(5):1321-8. DOI: 10.1378/chest.115.5.1321. View

12.

MOSS A, DESILETS D, Higashino S, Ruttenberg H, Marcano B, DOOLEY R . Intrapulmonary shunts in cystic fibrosis. Pediatrics. 1968; 41(2):438-45. View

13.

Homma A, Anzueto A, Peters J, Susanto I, Sako E, Zabalgoitia M . Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. J Heart Lung Transplant. 2001; 20(8):833-9. DOI: 10.1016/s1053-2498(01)00274-1. View

14.

Adler F, Aurora P, Barker D, Barr M, Blackwell L, Bosma O . Lung transplantation for cystic fibrosis. Proc Am Thorac Soc. 2009; 6(8):619-33. PMC: 2797068. DOI: 10.1513/pats.2009008-088TL. View

15.

Yankaskas J, Marshall B, Sufian B, Simon R, Rodman D . Cystic fibrosis adult care: consensus conference report. Chest. 2004; 125(1 Suppl):1S-39S. DOI: 10.1378/chest.125.1_suppl.1s. View

16.

Christie J, Edwards L, Aurora P, Dobbels F, Kirk R, Rahmel A . The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant. 2009; 28(10):1031-49. DOI: 10.1016/j.healun.2009.08.004. View

17.

Ben Tov A, Paret G, Sela B, Blau H, Hegesh J, Efrati O . N-terminal pro B-type natriuretic peptide (N-BNP) levels in cystic fibrosis patients. Pediatr Pulmonol. 2007; 42(8):699-703. DOI: 10.1002/ppul.20635. View

18.

Tonelli A, Fernandez-Bussy S, Lodhi S, Akindipe O, Carrie R, Hamilton K . Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survival. J Heart Lung Transplant. 2010; 29(8):865-72. DOI: 10.1016/j.healun.2010.04.006. View

19.

Flume P, Mogayzel Jr P, Robinson K, Rosenblatt R, Quittell L, Marshall B . Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010; 182(3):298-306. DOI: 10.1164/rccm.201002-0157OC. View

20.

Bright-Thomas R, Ray S, Webb A . Pulmonary artery pressure in cystic fibrosis adults: characteristics, clinical correlates and long-term follow-up. J Cyst Fibros. 2012; 11(6):532-8. DOI: 10.1016/j.jcf.2012.04.012. View